Table 3:

Baseline Disease Characteristics of Patients in SCLC Cohort in Study B-005

Characteristic, n (%)	All SCLC (N=105)	Sensitive CTFI ≥ 90 days (N=60)	Resistant CTFI <90 days (N=45)
SCLC stage at diagnosis
Extensive	73 (70%)	35 (58%)	38 (84%)
Limited	32 (30%)	25 (42%)	7 (16%)
Prior therapies
1 line	98 (93%)	57 (95%)	41 (91%)
2 lines	7 (7%)	3 (5%)	4 (9%)
Prior radiotherapy	76 (72%)	57 (95%)	19 (42%)
Prophylactic cranial irradiation	61 (58%)	47 (78%)	14 (31%)
Prior immunotherapy	8 (8%)	3 (5%)	5 (11%)

Abbreviations: SCLC: small cell lung cancer; CTFI: chemotherapy-free interval

Source: Drug Approval Package: ZEPZELCA (lurbinectedin) (Ref. 10)